US Patent

US7767700 — Method of providing pirfenidone therapy to a patient

Method of Use · Assigned to Intermune Inc · Expires 2027-12-18 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for decreasing adverse events associated with pirfenidone therapy through an optimized dose escalation scheme and a starter pack.

USPTO Abstract

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2080 —
U-2080 —
U-1601 —
U-2080 —

Patent Metadata

Patent number
US7767700
Jurisdiction
US
Classification
Method of Use
Expires
2027-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Intermune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.